Summary:

Three new anti-cancer drugs—Trastuzumab Deruxtecan, Osimertinib, Durvalumab—are added to List 1 of 2.5% Schedule. A new 6% entry is provided for extruded/expanded savoury products. Several adjustments are made in 9% Schedule, including revising entries for seats (9401) and excluding certain goods. A new 14% entry 9401 20 00 is added for motor vehicle seats. The changes update GST rates for pharma, food products, furniture, and automotive goods.

Issued for earlier notification?

Yes — amends Notification 01/2017–CT (Rate).